# Photodynamic Therapy-Induced Immune Modulation: Part III

> **NCT03643744** · PHASE1 · TERMINATED · sponsor: **Wright State University** · enrollment: 12 (actual)

## Conditions studied

- Actinic Keratosis
- Photodynamic Therapy

## Interventions

- **DRUG:** Celecoxib 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03643744
- **Lead sponsor:** Wright State University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-01
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Per PI due to data analysis results.
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643744, "Photodynamic Therapy-Induced Immune Modulation: Part III". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03643744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*